

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4628487

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	CHANGE OF NAME	
CONVEYING PARTY DATA		
	Name	Execution Date
	IO THERAPEUTICS, LLC	12/31/2010
RECEIVING PARTY DATA		
Name:	IO THERAPEUTICS, INC.	
Street Address:	25241 BUCKSKIN DRIVE	
City:	LAGUNA HILLS	
State/Country:	CALIFORNIA	
Postal Code:	92653	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	15629591	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949 253-0900	
Email:	ocpatents@klgates.com	
Correspondent Name:	K&L GATES LLP	
Address Line 1:	1 PARK PLAZA	
Address Line 2:	TWELFTH FLOOR	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	1958481.00046	
NAME OF SUBMITTER:	DOROTHY L. CHAMBERS	
SIGNATURE:	/DOROTHY L. CHAMBERS/	
DATE SIGNED:	10/05/2017	
Total Attachments: 3		
source=1958481_LLC_to_Inc#page1.tif		
source=1958481_LLC_to_Inc#page2.tif		
source=1958481_LLC_to_Inc#page3.tif		

WORLDWIDE PATENT ASSIGNMENT

WHEREAS, Io Therapeutics, LLC, with its principal place of business at 25241 Buckskin Drive, Laguna Hills, California 92653 (hereinafter referred to collectively as "ASSIGNOR") has acquired the entire right, title and interest in the patents in the attached APPENDIX;

AND WHEREAS Io Therapeutics, Inc., having a place of business at 25241 Buckskin Drive, Laguna Hills, California 92653 (hereafter, together with any successors, legal representatives or assigns thereof, called "ASSIGNEE") has an interest in acquiring the entire right, title and interest in the patents in the attached APPENDIX;

AND WHEREAS ASSIGNOR has an interest in transferring the entire right, title and interest in the patents in the attached APPENDIX.

NOW, THEREFORE, for valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer and set over to ASSIGNEE the entire right, title and interest in all United States Letters Patents in the APPENDIX and all reissues, reexaminations and extensions thereof, and the foreign equivalents set forth in the APPENDIX;

AND ASSIGNOR HEREBY covenants that they have full right to convey the entire interest in the patents in the APPENDIX hereto assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith;

AND ASSIGNOR HEREBY further covenants and agrees that it will communicate to ASSIGNEE any facts known to ASSIGNOR respecting patents in the APPENDIX and testify in any legal proceeding, sign all lawful papers, execute substitute and reissue applications, make all rightful oaths and generally do everything possible to aid ASSIGNEE to enforce proper patent protection in all countries.

IN TESTIMONY WHEREOF, I hereunder set my hand this 31st day of December, 2010.


Io Therapeutics, LLC

By: Roshantha A. Chandraratna
Roshantha A. Chandraratna, Manager

STATE OF CALIFORNIA)
) ss.
COUNTY OF ORANGE)

On this 31st day of December, 2010, before me, Lynn A. Bisnar, notary public, personally appeared **Roshantha A. Chandraratna** proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the foregoing instrument and acknowledged to me that he ~~she~~ executed the same in his ~~her~~ authorized capacity, and that by his ~~her~~ signature on the instrument the person or entity upon behalf of which the person acted, executed the instrument.

(SEAL)



Lynn A. Bisnar
Notary Public

PATENT

REEL: 043798 FRAME: 0070

APPENDIX

Application No. (Patent No.)	Title
U.S. 5,952,345 AU 1996-000072354 (713586) CA 1996-002230672 (2230672) CN 1996-000197896 (96197896.1) EP 1996-000933742 (0853610) JP 1996-000511258 U.S. 5,958,954 AU 1999-000019406 (744757) CA 1998-002316351 (2316351) EP 1998-000964231 (1042313) JP 1998-020005265 (4118511)	Synthesis and Use of Retinoid Compounds Having Negative Hormone and/or Antagonist Activities
U.S. 6,313,163 U.S. 5,917,082 U.S. 5,675,033 AU 1996-000060446 AU 1998-000090227 CA 1996-002223535 EP 1996-000918100 (0848696) JP 1996-000501376 (4052668)	2,4-Pentadienoic Acid Derivatives Having Retinoid-like Biological Activity
U.S. 6,387,950 AU 2001-000053045 CA 2001-002405136 (2405136) EP 2001-000926512 (1268405) EP 2001-005025970 JP 2001-000572454	Treatment of Tumors with RAR Alpha Selective Retinoid Compounds in Combination with other Anti-Tumor Agents
U.S. 5,856,490 AU 1996-000010560 (702499) CA 1996-002238274 (2238274) CN 1996-000199714 (96199714.1) EP 1996-000941408 (0876330) JP 1996-000519852 (4112003)	Aryl or Heteroaryl Amides of Tetrahydronaphthalene, Chroman, Thiochroman and 1,2,3,4-Tetrahydroquinoline Carboxylic Acids, Having an electron Withdrawing Substituent in the Aromatic or Heteroaromatic Moiety, Having Retinoid-Like Biological Activity
PCT/US2007/011730 CA 2,651,487 CN 200780022295.0 EP 07794936.0 JP 2009-511053	Use of a RAR Antagonist or Inverse Agonist for the Treatment of Chemotherapy and/or Radiation Therapy Side Effects (As Amended)
U.S. 12/291,994 U.S. 60/800,773	Methods for Treating Chemotherapy and Radiation Therapy Side Effects

1958481.00002
lo Therapeutics, LLC
Assignment to lo Therapeutics, Inc.

Application No. (Patent No.)	Title
U.S. 12/079,938 U.S. 60/722,264 PCT/US2006/038252 AU 2006299645 BR PI0616454-4 CN 200680044308.X EP 06825280.8 HK 08109267.9 JP 2008533721 MX 2008004154 NZ 567139	Treatment of Cancer with Specific RXR Agonists